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ABSTRACT
En masse analysis of gene structure and function by
array technologies will have a lasting and profound
effect on biology and medicine. This impact can be
compromised by low quality of probes within arrays,
whichweshowcanbecaused byincompleteremoval
of chemical protecting groups. To solve this quality
control problem, we present a sensitive, specific and
facile method to detect these groups in situ on arrays
using monoclonal antibodies and existing instru-
mentation. Screening of microarrays with these
monoclonal antibodies should guide the considera-
tion given to data derived from these and should
enhance the accuracy of the results obtained.
INTRODUCTION
During the chemical synthesis of DNA and RNA, branching
is prevented by ensuring that only one chemically reactive
group is present in the growing oligonucleotide and one in
the nucleoside 30-phosphoramidite. This is achieved by block-
ing other reactive groups within the sugars and bases (e.g.
exocyclic amines) with protecting groups. The removal of
the protecting groups that block exocyclic amines, commonly
known as deprotection, occurs only after synthesis. Addition-
ally, the 50-OH capping group in a newly incorporated nucle-
otide, usually 4,40-dimethoxytrityl (DMT), must be removed
prior to the addition of the next residue and at the completion
ofsynthesis.Althoughdecappinganddeprotectionareefﬁcient
reactions, the yield is not nearly 100%. Indeed, using mono-
clonal antibodies to speciﬁc protecting groups we previously
showed that oligonucleotides from commercial sources claim-
ingdeprotectionretainedsigniﬁcantlevelsofprotectinggroups
[see Refs (1,2); Barley-Maloney and Agris, in press]. This
antibody-based method was previous validated using high-
performance liquid chromatography (HPLC) (1). Whereas
this level of contamination may be adequate for routine
procedures, it isclearly notacceptable for diagnosticand prog-
nostic uses of oligonucleotides, such as arrays. These consid-
erations led us to ask two questions: (i) can we detect
remaining protecting groups in oligonucleotides printed on
arrays and (ii) do protecting groups alter array results?
MATERIALS AND METHODS
DetectionofDMTgroupsinsitu.CorningUltraGapglassslides
were spotted with the Operon Human Genome Array-Ready
Oligo Set (Version 2.0) and custom design oligonucleotides
on an Omnigrid 100 (GeneMachines) arrayer. The arrays
were washed in a pre-hybridization buffer (5· SSC, 0.1%
SDS, 1% BSA) for 1 h at 42 C. Arrays were washed in deion-
izedwaterandthenprobedwitha1:100dilution[inwashbuffer
(sodium phosphate, 0.9% NaCl, 0.5% Tween-20, 1% BSA)] of
anti-DMT (Ab 1-30-26) monoclonal hybridoma supernatant
(1) and incubated for 2 h at room temperature (RT). The arrays
were then washed three times with wash buffer. The secondary
antibody, goat anti-mouse conjugated 660 AlexaFluor
(Molecular Probes) was diluted in wash buffer (1:100 dilution)
and incubated on the array for 1 h at RT. Arrays were washed
according to protocols found at the Duke Microarray Facility
web site (http://microarray.genome.duke.edu/spotFolder/
protocolFolder/) and scanned on the Axon GenePix 4000B
scanner (Molecular Devices).
Labeling and hybridization
Labeling and hybridization protocols are further detailed at
the Duke Microarray Facility web site (http://microarray.
genome.duke.edu/spotFolder/protocolFolder/).
RESULTS AND DISCUSSION
The presence of protecting groups on arrays was tested
on glass slides spotted with the Operon Human Genome
Array-Ready Oligo Set (Version 2.0). On the same array
we spotted mixtures of decapped and deprotected b4-
thymosin and ribosomal protein L9 oligonucleotides, and
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oligonucleotides. The decapping and deprotection, which
meant the DMT cap and the protecting benzoyl- (Bz),
isobutiryl- (Ibu) and isopropropylphenoxyacetyl- (IprPAC)
groups had been removed, followed our previously published
procedure that was validated by HPLC (1). Near complete
deprotection of the ß4-thymosin and ribosomal protein L9
oligonucleotides was observed by gel electrophoresis and the
dot-blot antibody-based assay described previously (1) (data
not shown). Mixing of fully protected and completely depro-
tected oligonucleotides insured accurate determination of the
percentage of protecting groups in any mixture and
percentages from 2 to 100% were evaluated for detection
with a monoclonal antibody to the DMT group (1).
The DMT group in the b4-thymosin and ribosomal protein
L9 oligonucleotides was easily visualized by an anti-DMT
monoclonal antibody (Figure 1A, left panel) (see ﬁgure leg-
end for methods). DMT could be detected even with only
 10% of the DMT groups remaining (data not shown).
Whereas this signal was not easy to quantify in the Cy3 or
Cy5 channel it was obvious upon inspection of the spot
morphology in the Cy5 channel. The anti-DMT signal was
characterized by a yellow/green spot surrounded by a red
halo while the background signal observed with fully depro-
tected oligonucleotides was detected as a low intensity green
signal on the spots (Figure 1A, anti-DMT panels). The data
above led us to conclude that we could identify DMT groups
remaining on spotted oligonucleotides in situ.
Using this criterion, we detected the DMT signal, which
we deﬁned as spots containing a red halo, in only very
few spots ( 3 in 21 000) among oligonucleotides from the
Operon set. We surmise that these represent rare cases
where the supplied oligonucleotide was poorly deprotected
(Figure 1A, middle panel).
In order to ascertain the effect of incomplete protection
on array function, we analyzed the hybridization signals
obtained with two total RNA samples, which were labeled
and hybridized using standard direct labeling protocols.
First we evaluated spot morphology and this was found to
be normal for the majority of the oligonucleotides in the
Operon set (e.g. open arrow, Figure 1A, right panel). There
were no signs of spot spreading or poor spot morphology
due to printing techniques, thus we do not believe that the
halos observed above with anti-DMT antibody staining are
a result of poor printing quality. The same was true for
b4-thymosin and ribosomal protein L9 oligonucleotides that
were fully deprotected (0% protection in Figure 1B, hybrid-
ization panels); however, the protected oligonucleotides
resulted in aberrant spot morphology (closed arrow,
Figure 1A and B, hybridization panels). Anomalous spot
morphology is evident in spots that contain 20% protected
oligonucleotides and becomes extreme with higher levels of
protection (Figure 1C). We also noticed that the spots with
aberrant morphology yielded an altered ratio of medians, thus
giving a false indicator of expression (data not shown). Clearly
even modest levels of protecting groups led to aberrant spot
morphology and potentially altered expression data.
The alteration of medians suggested that protecting groups
would interfere with microarray performance. In order to
further test this, we measured the mean signal intensity for
the same mixtures of oligonucleotide probes (b4-thymosin
and ribosomal protein L9). The presence of protected
oligonucleotides clearly reduced the sum of the mean signal
intensity for both probes and a signiﬁcant reduction could
be seen at low levels of protection (Figure 2A and B). The
reduction in signal intensity correlated with aberrations in
spot morphology. Whereas we cannot conclude that the
DMT capping group was responsible for the observed reduc-
tion of signal and change in morphology, we can deduce that
incomplete removal of DMT, Bz, Ibu or IprPAC leads to
suboptimal microarray performance.
Whereas the method of mixing protected and deprotected
oligonucleotides provides a very precise measure of the per-
centage of protecting groups in a spot, it can only supply an
estimate of the untoward effects of protecting groups on
probe performance. In one spot where each oligonucleotide
is 10% protected hybridization of each oligonucleotide within
the spot is likely to be affected and therefore we argue that
the negative effect on hybridization will be greater than
effects for a spot where 10% of the oligonucleotides are
Figure 1. Detection of DMT groups in spotted oligonucleotides. (A) Left
panel: shown is a section of an spotted array probed with anti-DMT (Ab 1-30-
26) monoclonal hybridoma supernatant (1). Middle panel: a section of the
Human Operon v2.0 oligonucleotide array that contains an oligonucleotide
that displayed a red halo when probed for DMT groups as described for the
left panel. Right panel: hybridization of a cDNA probe to the Human Operon
oligonucleotide v2.0 array is shown. An open arrow points to the normal
hybridization of a cDNA probe to an oligonucleotide of unknown protection
status. Closed arrow represents the location of a series of oligonucleotides,
which possess varying amounts of DMT, Bz, Ibu, and IprPAC groups
(0–100%). (B) Top panels represents sections of the arrays with ribosomal
protein L9 and b4-thymosin oligonucleotides that contain varying amounts of
DMT, Bz, Ibu and IprPAC groups (0, 80 and 2%) and were probed with anti-
DMT monoclonal antibody (see text). Bottom panels represent hybridization
of a cDNA probe to the same region of the array. Antibody probing, and
cDNA probe labeling and hybridization protocols were described above.
(C) Spot morphology of a series of oligonucleotides with 0–100% protection.
cDNA probe labeling and hybridization protocols were described above.
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provide an underestimate of the negative effects of incom-
plete deprotection. This also means, however, that at this
time we cannot give a strict criterion for rejection of a
probe other than visual inspection and exclusion of any
spot that produces a characteristic halo as seen in Figure 1.
The wide use and the formidable potential of microarray
technologies has led to appropriate concern with microarray
quality control (3,4). Issues of statistical power and biological
variation have been carefully considered and the overall value
of microarray data has been well validated. Nonetheless,
the standards for use in therapy and diagnosis will have to be
developed and will likely be more rigorous than current best
practices (3). The quality of the oligonucleotides, whether
pre-made and spotted, or synthesized in situ have begun to be
analyzed. Pre-screening with DNA-binding ﬂuorescent dyes
can be used to interrogate arrays for spot morphology and for
some level of quality and quantity per spot (5,6). Statistical
methods (7,8) and ab initio calculations (9,10) can be used to
identify poorly performing oligonucleotides or even regions
of arrays. To date, however, there has been little discussion
of incomplete deprotection in microarrays. In this report we
showthatincompletedeprotectioncouldleadtopoorarrayper-
formance and, more importantly, we provide a methodology to
detect it. While we limit our conclusions to DNA oligonu-
cleotide spotted arrays, the potential for incomplete deprotec-
tion can also exist in arrays where oligonucleotide synthesis
is carried out on the solid support. In fact, the signiﬁcant nega-
tive functional consequences of incomplete deprotection may
be exacerbated in these microarrays because of the shorter
length of the oligonucleotides.
We suggest that screening of microarrays with monoclonal
antibodies to identify protecting groups should guide the
consideration given to data derived from individual features
and should enhance the accuracy of the results obtained.
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Figure 2. Protecting groups interfere with array function. (A) A regression analysis of the sum of median signal intensity from differentially protected (0–100%
DMT, Bz, Ibu and IprPAC) b4-thymosin oligonucleotides that were hybridized with a cDNA probe. Data points represent triplicate experiments; variation within
signal intensities is represented by error bars. (B) A regression analysis of the sum of median signal intensity from differentially protected (0–100% DMT, Bz,
Ibu and IprPAC) ribosomal protein L9 oligonucleotides that were hybridized with a cDNA probe. Data points represent triplicate experiments; variation within
signal intensities is represented by error bars.
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